Vanderbilt’s Warren Center Inks CNS-based Drug Development Deal with ACADIA Pharmaceuticals Showcasing their “De-Risking” Model

In an effort to develop and commercialize central nervous system disorder therapies, such as Alzheimer’s disease and schizophrenia, Vanderbilt University’s Warren Center for Neuroscience Drug Discovery (VCNDD) entered into an exclusive worldwide licensing and...

Pin It on Pinterest